李氏大药厂(00950.HK)签订授权许可协议及出售附属股权
李氏大药厂(00950.HK)公布,全资附属Lee’s International及间接全资附属兆科广州作为被授权人,与外商独资企业及Zhaoke Ophthalmology订立授权许可协议。根据协议,授权人同意向被授权人授出有关授权产品於授权地区的独家许可权,作为代价,被授权人同意根据授权许可协议的条款向授权人支付预付金1,000万美元,将以股份购回方式或现金支付,另有里程金500万美元及销售佣金。
公司表示,股份购回将构成Lee’s International出售Zhaoke Ophthalmology股权的出售事项。假设兆科A系列优先股获全数转换,公司透过Lee’s International於Zhaoke Ophthalmology的间接权益为50.117%,而Zhaoke Ophthalmology为公司的间接非全资附属公司。
於股份购回完成後,公司於Zhaoke Ophthalmology的间接权益将由约50.117%下降至48.539%,Zhaoke Ophthalmology将不再为公司的间接非全资附属公司,而兆科集团的财务业绩亦不会於公司的综合财务报表中综合入账。公司估计,出售事项将录得1.86亿元收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.